Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - USD ($) $ in Millions			12 Months Ended
		Dec. 14, 2023	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairments			$ 3,008
Amortization expense for finite-lived intangible assets			4,700
Seagen [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period increase (decrease)		$ 28,800
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairments	[1]		1,184
Developed Technology Rights [Member] | Seagen [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets period increase (decrease)		7,500
Licensing Agreements and Other [Member] | Seagen [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets period increase (decrease)		450
IPR&D [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairments	[1]		1,704
IPR&D [Member] | Seagen [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period increase (decrease)		$ 20,800
Zavzpret [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets period increase (decrease)			450
Finite-lived intangible assets, capitalized milestone			495
Zavzpret [Member] | IPR&D [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period increase (decrease)			450
Etrasimod (Velsipity) [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairments			1,400
Etrasimod (Velsipity) [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets period increase (decrease)			3,600
Etrasimod (Velsipity) [Member] | IPR&D [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period increase (decrease)			3,600
Padcev [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets period increase (decrease)			2,100
Padcev [Member] | IPR&D [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period increase (decrease)			2,100
Bratovi/Mektovi [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets period increase (decrease)			1,100
Bratovi/Mektovi [Member] | IPR&D [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period increase (decrease)			1,100
Prevnar 13 [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset impairments			$ 964

[1] Reflects intangible assets written down to fair value in 2023. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.